Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AB Science Reports Positive Phase 2 Results for Masitinib in COVID-19
Details : AB1010 (masitinib) is a small molecule drug that selectively inhibits specific tyrosine kinases such as colony-stimulating factor 1 receptor, being evaluated with Isoquercetin for COVID-19.
Brand Name : AB1010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2024
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, the main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in the world that specifically ...
Brand Name : AB1010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in world that specifically targets this...
Brand Name : AB1010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2022
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AB Science Receives Regulatory Authorization to Commence a Second Phase 2 Covid-19 Study
Details : Masitinib is being developed as a novel SARS-CoV-2 protease inhibitor antiviral therapy in non-hospitalized (non-severe) and hospitalized (severe) COVID-19 patients. Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and...
Brand Name : AB20001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2021
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration
Details : SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.
Brand Name : ISQ950AN
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 04, 2021
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : FDA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University of Chicago
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This collaboration follows the discovery by the University of Chicago that masitinib inhibits the main protease (3CLpro) necessary for the SARS-CoV-2 viral replication cycle.
Brand Name : AB20001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 06, 2021
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University of Chicago
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Quercis Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.
Brand Name : ISQ950AN
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2021
Lead Product(s) : Isoquercitrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Quercis Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Agreement
EIB Supports AB Science in its COVID-19 Development Programme
Details : This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.
Brand Name : AB1010
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking vira...
Brand Name : AB1010
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 02, 2020
Lead Product(s) : Masitinib Mesylate,Isoquercitrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?